Responses to molecularly targeted therapies can be highly variable and depend on mutations, fluctuations in target protein levels in individual cells and drug delivery. The ability to rapidly quantitate drug response in cells harvested from patients in a point-of-care setting would have far reaching implications. Capitalizing on recent developments with miniaturized NMR technologies, we have developed a magnetic nanoparticle based approach to directly measure both target expression and drug binding in scant human cells. The method involves covalent conjugation of the small molecule drug to a magnetic nanoparticle that is then used as a read out for target expression and drug binding affinity. Using poly(ADP-ribose) polymerase (PARP) inhibition as a model system, we developed an approach to distinguish differential expression of PARP in scant cells with excellent correlation to gold standards, the ability to mimic drug pharmacodynamics exvivo through competitive target-drug binding, and the potential to perform such measurements in clinical samples. Nanomaterials have become an indispensable tool in the development of clinical diagnostics, 1-3 single cell analysis 4, 5 and systems wide analysis of clinical specimen. 6 They can be easily modified with multivalent targeting ligands to amplify signals, 7 improve avidity, 4, 5 enhance binding, 8 and translate molecular interactions into measurable electrical, optical or magnetic signals. In particular, magnetofluorescent nanoparticles allow for dual read-outs by optical (e.g. flow cytometry, immunofluorescence) and magnetic sensing (e.g. nuclear magnetic resonance or magnetoresistive detection). Dextran-coated, cross-linked iron oxide (CLIO) nanoparticles have been shown to be ideal for use with clinical samples as they are highly stable in physiological buffers and can be easily detected by NMR measurements with low biological background. Recently, our group leveraged these properties to profile scant cells from fine needle aspirate 3 and to enhance detection of rare circulating cancer cells. Most nanoparticle-based diagnostic applications have primarily used antibodies as affinity ligands to detect whole cells, 3 pathogens, 9, 10 soluble protein biomarkers 11 or metabolites. 12
One major unexplored application, has been the use of nanomaterials to quantitatively assay drug-target binding in clinical samples. Though clinical samples are readily procured during routine medical procedures, samples often have scant cells with short half-lives once harvested, 13 thus necessitating a point-of-care assay with minimal sample processing. Tools to quantify target-binding in a given patient at a given dose could help in screening drug candidates during pharmaceutical development 14 and also impact treatment decisions made in the clinic. Ultimately such assays would significantly aid in determining whether systemically administered drugs have reached and occupied their intended cellular targets and how target binding varies across patients who may have acquired drug resistance.
In order to enable fast, point-of-care assessment of drug-target interactions, we designed nanosensors that could be adapted to study many drug-target systems which are quickly assayed by a portable diagnostic NMR system (DMR). 9, 15 Specifically, we hypothesized that by constructing a single small molecule drug-nanoparticle conjugate that could compete with corresponding free small molecules for their targets, one could gain insights into the molecular binding action of the drugs. Given the vast repositories of small molecules drugs, nanosensors could thus be developed for a variety of targets. Furthermore, we reasoned that the drugs themselves could serve as "affinity ligands", and aimed at establishing a new biomarker detection paradigm distinct from antibodies. 4 Unlike antibodies which show binding specificity for single antigenic sites within a given protein, small molecule drugs bind to specific conformations (e.g. catalytic sites) and often show broader specificity. Using the drug itself as a probe allows for a combined read out of multiple relevant targets all of which may affect drug efficacy.
As a model system, we selected poly(ADP-ribose) polymerase (PARP) inhibition, and conjugated the PARP inhibitor Olaparib (AZD-2281) to magnetic nanoparticles. Several PARP inhibitors have made significant headway in pre-clinical and clinical trials for ovarian and breast cancer. [16] [17] [18] [19] Moreover, the binding kinetics of PARP inhibitors are particularly interesting as they have been designed to mimic nicotinamide and competitively block binding at specifically the PARP1 and PARP2 catalytic sites. 20 Using the PARPnanosensor, we performed validation experiments, comparative drug inhibition studies and testing in whole blood samples without the need for prior purification. We show that the method is fast, sensitive and well suited for point-of care operation. The ability to measure target binding of an increasing number of molecularly targeted drugs should have a range of applications in biomedicine, drug development, clinical trials and for routine patient care.
Results and Discussion

Synthesis and characterization of the PARP nanosensor
Based on earlier findings that the 4-NH-piperazine functionality of AZD2281 tolerates bulky substituents without significant decrease in binding affinity, [21] [22] [23] we chose this site to immobilize the small molecule. For this reason, carboxyl-functionalized precursor 1 was reacted with N-hydroxy succinimide in the presence of a carbodiimide resin, yielding the amine reactive NHS ester activated AZD2281 derivative AZD2281-NHS 2 (Fig. 1a) . HPLC, ESI-MS and HRMS spectra confirmed both identity and purity of the isolated product. AZD2281-NHS was converted to PARPi-NP 3 by addition of amine-terminated CLIO nanoparticles (Fig. 1a) . Each nanoparticle had approximately 70 drug molecules covalently attached, which corresponds to near complete conversion of free amine groups on each particle. The AZD-2281 conjugated nanoparticles (PARPi-NPs) were highly stable in solution (>6 months) without detectable aggregation, as determined by dynamic light scattering (mean diameter: 40.1 nm). Control NPs used for all studies were succinylated, but otherwise identical. Carboxylic acid modified AZD-2281 had an IC 50 of 6.7 nM, similar to that of the reported free AZD-2281 drug (5 nM). 21, 24 Following conjugation to the nanoparticle, the construct retained inhibitory activity against PARP1 with a measured IC 50 of 3 nM (Fig. 1c) . Importantly, none of the control nanoparticles (either the succinylated or amine precursor CLIO) showed any inhibition of PARP activity. Further characterization of the nanoparticles is included in supplementary information (Fig. S1) .
Validation of the drug nanosensor in cell lines
We first determined whether the nanosensor could be used to measure PARP expression as well as pharmacological inhibition of PARP by small molecules. We selected five cell lines (HT29, HeLa, MDA-MB-231, MDA-MB-436 and HEK293 cells) that have varying PARP1 expression levels as confirmed by Western Blotting (Figs. 2a, b) . Cells were fixed, permeabilized, and then incubated with either PARPi-NP or control-NP. The PARPi-NPs had an average diameter of about 40 nm, which is slightly larger than an unconstricted, open nuclear pore size of 30 nm. 25 However, once permeabilized, nanoparticles are able to freely enter the cell by diffusion for both nuclear and cytoplasmic targets. 26 Incubation times and nanoparticle concentrations were selected to achieve maximal target binding from the PARPi-NP with minimal background from the control-NP. PARPi-NPs showed tight binding to the target with little decrease in signal over time. Following the removal of excess NPs, samples were processed by the DMR system to determine their transverse relaxation time (T 2 ). The measured T 2 values were converted to R 2 (=1/T 2 ) and normalized to PBS and control-NP samples to obtain the PARP1 cellular expression level (Fig. 2c ). Fig. 2d shows excellent correlation between DMR magnetic measurements and PARP1 expression levels as determined by Western Blots (r 2 = 0.92) and flow cytometry (r 2 = 0.97). DMR measurements were performed with 10,000 cells for validation studies; however, in subsequent experiments signals were detected in as few as 1,500 cells. In addition to PARP-1 measurements, we also determined PARP2 expression levels by immunoblotting (Fig. 2b) . However, correlation of PARPi-NP to expression was dominated by PARP1, likely due to the much higher abundance of PARP1 as compared to PARP2 in the selected cell lines.
We next used microscopy to further assess quantitative measurements by examining the intracellular localization of nanosensor and drug targets. In HEK293 cells with high PARP expression (Fig. 3a) , there was excellent co-localization between intracellular PARP1 antibody and PARPi-NP (co-localization correlation = 0.8). The nanosensor showed strong nucleolar and and nuclear localization, which is consistent with PARP1 subcellular organization as previously found using PARP1 expressing cell lines 27, 28 or AZD-2281 as a fluorescent probe. 23 Similar trends were observed in HeLa cells, which have moderate PARP1 expression. In HT29 cells which have little PARP expression, both the PARP1 antibody and PARPi-NP showed negligible signal. The control-NP showed little to no background (Fig 3b) .
Testing different small molecule PARP inhibitors using the nanosensor
Most small molecule PARP inhibitors work by competitively inhibiting nicotinamide (NAD +) at the PARP catalytic site. 29 We chose 5 different, commercially available PARP inhibitors (Fig. 4) to test whether the nanosensor-DMR measurements could be used to determine IC 50 of each of the different drugs. Briefly, cells were incubated with varying doses of a PARP inhibitor. Subsequently, PARPi-NPs were added to detect the number of unoccupied PARP targets. The entire assay was performed in less than 90 minutes and required only 10,000 cells. The key PARP inhibitor, AZD2281 showed an IC 50 of 1.14 nM and was able to effectively compete the PARPi-NP in a homologous binding competition assay (Fig 4) . AG-014699 which has high structural similarity to AZD-2281 also displayed very tight binding with an IC 50 of 0.67 nM. The heterologous competitive binding curve with ABT-888 (Velaparib), another competitive PARP inhibitor, showed an IC 50 of 9.5 nM.
This data suggests that ABT-888 may have a faster off rate than that of PARPi-NP, in turn allowing the PARPi-NP to occupy more PARP sites for a given concentration of free ABT-888. Furthermore, unlike AZD-2281, ABT-888 has been reported to have a slightly stronger binding affinity for PARP-2 as opposed to PARP-1 due to a stronger interaction with alpha-helix-5 in the PARP-2/ABT-888 co-crystalstructure. 30 This difference in binding affinity for the two PARP targets could also explain why it has less of a competitive effect on the PARPi-NP compared to AZD-2281 or AG-014699. The weak PARP inhibitor, 3-aminobenzamide, which is similar in structure to NAD+ only showed a competitive effect at extremely high doses (IC 50 =29.5 μM). As a negative control, we also demonstrated that the non-competitive inhibitor BSI-201 (4-iodo-3-nitro-benzamide), which has a distinct pharmacophore and acts by ejecting the first zinc-finger of the PARP1 protein, 31 does not block PARPi-NP binding even at high doses. These results indicate that the nanosensor can indeed be used to quantitate target inhibition in competitive experiments.
Drug inhibition in live cells and blood samples
A number of strategies are currently used to measure target binding, including fluorogenic assays, ELISA, radioimmunoassays, mass spectrometry, SILAC, surface plasmon resonance and isothermal calorimetric measurements. These methods typically require purified target protein which necessitates a large number of cells and makes it difficult to perform assays under biologically relevant conditions. Consequently, few of these methods are ever performed in a clinical setting where there are time constraints, complexities in obtaining clinical samples, and limited numbers of cells.
The simplicity and the robustness of the nanosensor confer potential for the assay to be an effective platform to directly assess drug binding efficacy in patient samples. To evaluate its clinical utility, we measured target inhibition of AZD-2281 in mock clinical samples. Specifically, the ovarian cancer cell lines A2780, OVCAR429 and UCI-101 or the breast cancer cell line MDA-MB-231 were spiked into human whole blood. The samples were immediately treated with AZD-2281 drug at three different doses: 0 (probing dose), 150 nM (testing dose), and 1.5 μM (saturating dose). We used this "three-dose assay" rather than a full dose response curve (see Fig. 4 ) to speed up analysis and preserve valuable scant clinical samples. After removing excess AZD-2281, the PARPi-NPs were used to probe PARP sites unoccupied by the free drug (Figure 5a ). Finally, cancer cells were isolated using CD45 negative selection to remove host cells. While all prior in-vitro validation DMR assays were performed with 10,000 cells, signals from whole blood samples were detected with as few as 1,500 cells. This detection level is promising for clinical samples such as fine needle aspirate where one obtains about 1,500 per pass. 3 Though host cells (CD45+) showed little to no uptake of the PARPi-NP, CD45 negative selection was necessary to reliably detect changes in signal from the PARPi-NP after drug inhibition.
The result at the probing dose ([AZD-2281] = 0 nM; Fig. S3a ) revealed differences in PARP expression across the cell lines, which could serve as a predictive biomarker for initiating treatment. Indeed, prior work has correlated PARP levels to treatment sensitivity and patient outcome. 32, 33 The drug binding levels at the testing and saturating doses were then estimated by comparing R 2 values between drug-treated and untreated samples ( Supplementary Fig. S4b ). At the saturating dose, the binding levels reached a near maximum of 70% in almost all cell lines, except A2780 which showed only moderate drug binding (~40%). At the test dose, however, drug binding levels varied significantly across tumor lines, presumably reflecting differences in drug uptake as a result of varying expression in drug transporters, or variability in binding affinity due to mutations at the catalytic site. We then converted these values into a potential measure of drug binding efficacy by taking the ratio of drug binding levels between the test and the saturating doses (Fig. 5b) . These results suggest the potential for a future "treatment index," where patients with high drug binding efficacy would receive lower therapeutic doses, while patients with low drug binding efficacy would require higher doses, or be candidates to receive alternative drugs. In the future we plan to combine this assay with a previously developed assay 26 using two-step antibody-nanoparticle labeling to detect target expression. In this way, we will be able to discriminate low signals as a result of diminished drug binding as opposed to decreased expression of the target protein.
The described approach lays the groundwork for further advances. The sensitivity of the assay could be further enhanced by adopting two step bioorthogonal systems. In the first step, the drug could compete with a drug-trans-cyclooctene (TCO) conjugate of similar size with reduced steric constraints. In a second step, a Tetrazine (Tz)-NP could "click" with the drug-TCO to reveal target binding. Such two step systems have been shown to have a dramatic improvement in sensitivity over direct conjugates; 7 moreover, PARPi-TCO molecules have already been described. 23 A second consideration is the fact that current read-out happens as an average in several hundred to thousand of cells. In the future, we hope to combine the assay with newer generations of ultra-high sensitivity DMR and other magnetic technologies that would allow for single cell sensing of drug binding. 15 This sensitivity could potentially allow for early identification of rare drug resistant clones where the target protein contains mutations in the drug binding pocket or the resistant cells display an increase in drug efflux pumps. Finally, in the current work we have focused solely on drug target binding, but not on therapeutic efficacy. It would thus be of interest to combine the current assay with molecular profiling of several protein biomarkers to measure drug response. For example, one could assay cellular phenotypes to drug response such as apoptosis induction via measurements of cleaved caspases and cleaved PARP or PI3K/MAP kinase inhibition using measurements of key signaling pathway proteins such as phosphos6rp. 26 We believe that the described method could serve as a broader platform generalizeable to other drugs and their targets. The main challenges in adapting the assay to other drug or cellular systems are 1) the ability to modify the drug while retaining target specificity, tight binding, and stability in aqueous buffers and 2) optimization of assay conditions to ensure optimal nanoparticle binding for each target system. For some proteins, steric hinderance from the nanoparticles may be an issue for targets proteins with small binding pockets. This could be overcome by implementing two-step labeling with click chemistries. Recently, we have shown this to be possible for a variety of targets, e.g. Taxol, 34 PARP1 22, 35, 36 or PLK1 inhibitors. 37 Each target-inhibitor system would also require optimization of drug and nanoparticle concentrations, incubation times and cell permeabilization levels to ensure that nanoparticle binding is not assay-limited. Notably, an inherent benefit of the assay is that just one drug conjugate is required to survey several inhibitors of a particular target (Fig. 4) . Thus, there is flexibility during assay development to select a drug that is both optimal for the target system, yet easy to work with. In the future, we believe the assay can be extended beyond cancer cells, and used in other organisms such as bacteria to assay antibiotic resistance.
The ability to provide such data in biologically relevant samples could be of considerable clinical interest to make rational treatment decisions, optimize doses in a given patient and understand population heterogeneities of drug responses. The method could also serve to quantitate the effective drug target resident time in readily accessible samples such as peripheral blood. In sum, we designed and developed a paradigm using small molecule nanoparticle conjugates that have the potential to address several clinical limitations and to impact patient treatment.
Materials and Methods
Materials
The cell lines HT29, MDA-MB-231, MDA-MB-436, HeLa, HEK293, UCI-101, A2780, and OVCAR429 were all obtained from ATCC and cultured in RPMI (MDA-MBA-231, MDA-MB-436, OVCAR429, A2780, UCI-101) or DMEM (HT29, HeLa, HEK293) with 10% fetal bovine serum, 1% L-glutamine and 1% penicillin. The small molecule drug AZD-2281 modified with the NHS-ester was synthesized in-house. Free AZD2281 (Selleck), BSI-201 (ChemieTek), AG04699 (ChemieTek) and 3-aminobenzamide (Sigma) were all commercially purchased for use in competition assays. Until otherwise noted, all reagents were purchased from Sigma-Aldrich (St. Louis, MO) and used without further purification. Cyclohexylcarbodiimide polystyrene resin was purchased from EMD biosciences (Gibbstown, NJ). 4-[[4-Fluoro-3-(4-(5-oxopentanamide)piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one was synthesized according to published literature procedures. 23 Proton nuclear magnetic resonance ( 1 H NMR) spectra were recorded on a Varian AS-400 (400 MHz) spectrometer. Chemical shifts for protons are reported in parts per million (ppm) and are referenced against the dimethylsulfoxide lock signal ( 
NP Synthesis
Cross-linked iron oxide (CLIO) nanoparticles were synthesized and tagged with with an amine reactive cyanine dye (VivoTag 580xL, VT680xL, Perkin Elmer) as previously described. 7 Magnetofluorescent nanoparticles were reacted with 370 equivalents of AZD2281-NHS in PBS with 5% dimethylformamide (DMF) for 4h at room temperature. Excess AZD2281-NHS was removed using 100kD ultracentrifugation filtration units (Amicon) washed three times with PBS at 2000 rcf for 10 minutes and subsequently passed through a Sephadex G50 column.
NP Characterization
Nanoparticle concentration was determined by measuring iron content through absorbance at a characteristic wavelength of 400nm as previously established. 38, 39 Drug loading was determined by measuring the change in absorbance between the conjugated and unconjugated nanoparticle at 275nm. This change in absorbance was normalized by the amount of CLIO per sample, as calculated previously using iron concentration (UV absorbance at 400nm). 38 Molecules of AZD-2281 per nanoparticle were determined using a standard curve for the unreacted AZD-2281-NHS-ester. Drug inhibitory activity was confirmed by testing the ability of AZD2281-NP to inhibit PARP activity using an standard, in-vitro plate assay (Trevigen). Nanoparticle size was measured using dynamic light scattering (Malvern) (Fig. S1 ).
Cell labeling
Cells were grown in culture for 3 days up to 90% confluency before collection with 0.05% Trypsin/0.53 mM EDTA, and washed once with Stain Buffer, SB+ (PBS + 2% FBS + 1% BSA). Cells were then fixed with a 1:1 mixture of PBS with a formaldehyde based fix buffer (FBI, BD Biosciences) for 20 minutes at room temperature and permeabilized by washing twice with a saponin containing buffer with 1% BSA (PW+) (Perm/Wash Buffer, BD Biosciences). Each sample (250,000 cells/sample) was then labeled with 15 μg Fe/ml of nanoparticle (PARPi-NP, or Control-NP) in PW+, and incubated at room temperature protected from light on a rocker for 20 minutes. Excess nanoparticle was removed with two washes of PW+ before a final wash and resuspension in PBS (or Stain Buffer).
For the competition assay, HEK293 cells were treated with varying concentrations from 0 to 100 μM of various PARP inhibitors. Solutions were made up in PW+. After a 20 minute incubation at room temperature with the free inhibitor, the targeted PARPi-NP or Control NP were added to the same mix for a total concentration of 15 μg Fe/ml and incubated for an additional 20 minutes before washing and continuing with labeling as described above. Data shown represents at least biological duplicates and experiments were repeated at least three times. All data was fitted using Prism 5.0 (GraphPad, La Jolla, CA).
Immunoblotting
Lysates were collected from cells at 90% confluency by washing with cold PBS on ice and scraping with Ripa buffer containing a protease inhibitor cocktail. Samples were syringed 3 to 5 times and sonicated for 30 seconds before being spun down at 10,000 rpm for 15 minutes to collect the supernatant. Samples were made up with 4x Laemlli buffer with DTT and boiled for 10 minutes. Ten μg of total protein was loaded on NuPAGE 4-12% gradient Bis-Tris gels (Invitrogen) with MOPS running buffer and transferred to PVDF membrane using an iBlot Gel Transfer Device (Invitrogen). Blots were blocked with 5% dried milk in TBST (TBS with 0.1% Tween-20) and probed with primary monoclonal antibodies at the appropriate dilutions (PARP1, Santa Cruz Biotechnology sc7150, 1:250; PARP2, Abcam ab93416, 1:250, Beta-tubulin, Abcam ab7287, 1:100). Relative expression for each blot quantified using ImageJ (NIH).To ensure consistency in PARP expression, cell lysates were collected within four passages of the PARPi-NP detection. Data shown is representative of biological triplicate and is displayed as mean ± standard error.
Flow Cytometry
To determine target binding, the amount of nanoparticle present was quantified from VT680 fluorescence with an LSRII flow cytometer (Becton Dickinson) and the geometric mean of fluorescence intensity was determined using FlowJo software. All measurements were performed in biological triplicate and signals were normalized by the Control NP sample (S PARPi-NP /S Control-NP ). Data are shown as mean ± standard error.
Microscopy
Cells were labeled with nanoparticle as described above, and then incubated for 1 hour at room temperature with a PARP1 antibody (Santa Cruz Biotechnology sc8007) at a dilution of 1:50 in PW+. Cells were washed once with PW+ and then incubated with secondary antibody at 2ug/ml for half an hour on ice. Cells were washed two more times with PW+ before resuspension in PBS. A minimal volume (100 μL) of sample containing approximately 10,000 cells was transferred to a 96 well plate and imaged . Images were acquired at 40x with DeltaVision screening system (Applied Precision Instruments) and analyzed using FIJI software (version 1.45).
DMR
Magnetic detection measurements were conducted as described previously 3 with 10,000 cells using the miniaturized nuclear magnetic resonance device, DMR, 9 for target expression and competitive binding experiments. Detection in whole blood studies were performed with detection of as few as 1,500 cells. Signals were calculated by converting T 2 measurements to R 2 and compared the change in R 2 from the baseline PBS sample to the labeled PARPi-NP (S PARPi-NP ) or Control-NP (S Control-NP ). Signals from the PARPi-NP were normalized by dividing by the signal from the Control-NP (S PARPi-NP /S Control-NP ). Data shown is in biological duplicate and is represented as means ± standard error.
Whole Blood Processing
Selected cell lines (A2780, UCI-101, OVCAR429 and MDA-MB-231) were spiked into human whole blood samples (200,000 cells in 1.5mL). Samples were then either left untreated, or incubated with AZD-2281 at 155 nM and 1.5 μM for 30 minutes at room temperature. Following drug incubation, red blood cells were partially lysed with an RBC lysis agent (Qiagen), the sample was washed with SB+. The sample was then divided into two samples and probed either with PARPi-NP or Control-NP at 5 μg Fe/mL in 0.2x PW+ for 60 minutes. Samples were washed twice with 0.2x PW+ before resuspension in SB+ (or PBS). CD45 Negative selection was performed by using CD45 magnetic beads and LS columns (Miltenyi Biotec). Signals from CD45+ cell samples were then measured by flow cytometry or DMR.
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Refer to Web version on PubMed Central for supplementary material. was determined by the change in compared to PBS (R 2, NP -R 2, PBS ), and this value was normalized to the control-NP (S PARPi-NP /S control-NP ). Data shown is in biological duplicate from three separate DMR measurements. d) PARPi-NP was also optically assayed using flow cytometry (Supporting Information Figure S1 ) and shows high correlation to DMR measurements (r 2 =0.97). DMR measurements also had high correlation (r 2 =0.92) to PARP-1 expression from immunoblotting. Dotted lines represent 95% confidence intervals. Competitive binding assays were performed by incubating PARP inhibitors designed to compete with nicotinamide at the PARP-1 and PARP-2 catalytic pockets (AZD2281, AG04699 and ABT888). Another weak competitor, 3-aminobenzamide was selected, as well as the non-competitive inhibitor BSI-201 as a negative control. Free PARPi was added at various doses for 30 minutes before addition of the PARPi-NP or control-NP (15 μg Fe/ml). After 20 minutes of incubation and washing, signal was read magnetically using DMR. Competitive binding curves were fit using Prism (GraphPad); AZD-2281 had an IC50 of 3.4 nM (r 2 =.86), AG014699 had an IC50 of 7.0nM (r 2 =.84), and ABT-888 had an IC50 of 257nM(r 2 =.88). 3-aminobenzamide was only weakly competitive and BSI-201 had no competitive effect. Experiments were performed on three separate occasions and represent at least biological duplicate. Fluorescence measurements of the PARPi-NP competition assay are included in Supporting Information ( Figure S3 ). Mock clinical samples were prepared by spiking cancer cells into human whole blood. This sample was directly incubated with AZD-2281 before the PARPi-NP was added. Quick read-out could then be performed with DMR and/or flow cytometry. b) Drug binding levels were determined by looking at the inverse percent change in PARPi-NP from treated versus untreated samples. Data shown is an example of "Binding Efficacy" by taking the ratio of drug bound at the test dose to the saturating dose. OVCAR429 showed the highest drug binding at the test dose, and thus had a binding efficacy measure of 0.94. In contrast, no drug was bound to MDA-MB-231 at the test dose resulting in a binding efficacy of 0.00. With further validation, such a measure could be used as a simple diagnostic to dictate treatment choices in the clinic such as choice or dose of drug. Additional measurements of PARP expression and drug binding levels are included in Supporting Information ( Figure  S3 ).
